NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market
NKGen Biotech (OTC: NKGN) clarified that recent $0.00 price displays on some financial sites reflect quote dissemination limits on the OTC Expert Market, not the company’s underlying value. Quotations were moved to the OTC Expert Market on or about July 17, 2025 after the company failed to remain current in Exchange Act filings. The company confirmed its common stock remains listed and tradable, but public price quotes and volume are restricted to broker‑dealers and institutions. NKGen filed its Form 10‑K on October 8, 2025 and is working to file Form 10‑Qs for the quarters ended Mar 31, Jun 30, and Sep 30, 2025 to regain compliance and restore public market data access.
NKGen Biotech (OTC: NKGN) ha chiarito che gli ultimi display di prezzo $0,00 su alcuni siti finanziari riflettono limiti di diffusione delle quotazioni sul mercato OTC Expert, non il valore intrinseco della società. Le quotazioni sono state spostate sul OTC Expert Market intorno al 17 luglio 2025 dopo che la società non è riuscita a rimanere aggiornata nelle comunicazioni ai sensi della Exchange Act. L'azienda ha confermato che il suo titolo comune rimane quotato e negoziabile, ma le quotazioni pubbliche e il volume sono limitati a broker-dealers e istituzioni. NKGen ha presentato il Form 10-K il 8 ottobre 2025 ed è al lavoro per presentare i Form 10-Q per i trimestri chiusi il 31 mar, 30 giu e 30 set 2025 per tornare conforme e ripristinare l'accesso ai dati del mercato pubblico.
NKGen Biotech (OTC: NKGN) aclaró que las recientes pantallas de precio de 0,00 $ en algunos sitios financieros reflejan límites de difusión de cotizaciones en el OTC Expert Market, no el valor subyacente de la empresa. Las cotizaciones fueron movidas al OTC Expert Market alrededor del 17 de julio de 2025 después de que la empresa no logró mantener sus presentaciones conforme a la Ley de Intercambio (Exchange Act). La empresa confirmó que sus acciones comunes siguen cotizadas y negociables, pero las cotizaciones públicas y el volumen están restringidos a corredores-dealers e instituciones. NKGen presentó su Formulario 10-K el 8 de octubre de 2025 y está trabajando para presentar los Formularios 10-Q para los trimestres terminados el 31 de marzo, 30 de junio y 30 de septiembre de 2025 para volver a cumplir y restablecer el acceso a datos del mercado público.
NKGen Biotech (OTC: NKGN)은 최근 일부 금융 사이트에 표시된 $0.00 가격이 OTC Expert Market의 견적 배포 한계를 반영한 것이지, 회사의 내재 가치를 반영한 것이 아님을 명확히 했다. 견적은 회사가 Exchange Act 서류를 지속적으로 최신으로 유지하지 못한 이후 약 2025년 7월 17일경에 OTC Expert Market로 이동되었다. 회사는 보통주가 여전히 상장되어 있고 거래 가능하다고 확인했으나, 공개 가격 견적과 거래량은 브로커-딜러와 기관에만 제한된다. NKGen은 2025년 10월 8일에 Form 10-K를 제출했고, 준수 회복 및 공개 시장 데이터 접속을 복원하기 위해 2025년 3월 31일, 6월 30일, 9월 30일의 분기에 대해 Form 10-Q를 제출하기 위해 작업 중이다.
NKGen Biotech (OTC: NKGN) a précisé que les affichages de prix récents à 0,00 $ sur certains sites financiers reflètent des limites de diffusion des cotations sur le OTC Expert Market, et non la valeur intrinsèque de la société. Les cotations ont été déplacées vers le OTC Expert Market vers le 17 juillet 2025 après que la société n’a pas réussi à rester à jour dans les dépôts selon le Securities Exchange Act. La société a confirmé que ses actions ordinaires restent cotées et négociables, mais les cotations publiques et le volume sont restreints aux courtiers-déteneurs et aux institutions. NKGen a déposé son Form 10-K le 8 octobre 2025 et travaille à déposer les Form 10-Q pour les trimestres se terminant les 31 mars, 30 juin et 30 septembre 2025 afin de reprendre sa conformité et de rétablir l’accès aux données du marché public.
NKGen Biotech (OTC: NKGN) klärte, dass die jüngsten $0,00-Preis-Anzeigen auf einigen Finanzwebsites die Verbreitungsgrenzen von Kursen am OTC Expert Market widerspiegeln, nicht den inneren Wert des Unternehmens. Die Quotierungen wurden um den 17. Juli 2025 auf den OTC Expert Market verschoben, nachdem das Unternehmen die Einreichungen gemäß dem Exchange Act nicht aktuell halten konnte. Das Unternehmen bestätigte, dass seine Stammaktien weiterhin gelistet und handelbar bleiben, aber öffentliche Preisangebote und Volumen sind auf Broker-Dealer und Institutionen beschränkt. NKGen hat am 8. Oktober 2025 seinen Form 10-K eingereicht und arbeitet daran, die Form 10-Q für die Quartale beendet am 31. März, 30. Juni und 30. September 2025 einzureichen, um die Einhaltung wiederherzustellen und den Zugang zu Marktdaten für die Öffentlichkeit zu ermöglichen.
NKGen Biotech (OTC: NKGN) أوضحت أن عروض الأسعار الأخيرة بمقدار 0.00 دولار على بعض المواقع المالية تعكس قيود نشر الاقتباسات في OTC Expert Market، وليس القيمة الأساسية للشركة. تم نقل الأسعار إلى OTC Expert Market في حوالي 17 يوليو 2025 بعد أن فشلت الشركة في البقاء محدثة في إفصاءات قانون التبادل. أكدت الشركة أن أسهمها العادية تبقى مدرجة وقابلة للتداول، لكن الاقتباسات العامة وحجم التداول مقيدة للوسطاء والمؤسسات. قدمت NKGen النموذج 10-K في 8 أكتوبر 2025 وتعمل على تقديم نماذج 10-Q للربع المنتهي في 31 مارس و30 يونيو و30 سبتمبر 2025 لاستعادة الامتثال والوصول إلى بيانات السوق العامة.
NKGen Biotech (OTC: NKGN) 澄清，某些金融网站上最近显示的 $0.00 价格显示反映的是 在 OTC Expert Market 的报价传播限制，而不是公司的内在价值。报价大约在 2025年7月17日 日后被转移至 OTC Expert Market，因为公司未能在 Exchange Act 的备案中保持最新。公司确认其普通股仍然 上市并可交易，但公开价格报价和成交量仅限于经纪-交易商和机构。NKGen 已于 2025年10月8日 提交其 Form 10-K，并正在努力提交 截至 2025年3月31日、6月30日和9月30日的季度的 Form 10-Q，以重新合规并恢复对公开市场数据的访问。
- Filed Form 10‑K on October 8, 2025
- Common stock remains listed and tradable
- Working to file three missing Form 10‑Qs for Q1–Q3 2025
- Quotations moved to OTC Expert Market on or about July 17, 2025
- Public price quotes restricted, causing some sites to show a $0.00 price
- Did not meet Exchange Act filing requirements, triggering quotation restrictions
Insights
NKGen moved to OTC Expert Market due to filing lapses; Form 10-K filed and further filings planned to regain compliance.
NKGen Biotech had quotations moved to the OTC Expert Market because it missed required Exchange Act filings, which restricts public quote dissemination and makes retail price displays show $0.00 on many platforms. The Company states its Common Stock remains listed and tradable, but real-time public price and volume data are unavailable to most retail platforms.
The filing of the
Watch the completion and acceptance of the three Form 10-Q filings and any OTC notices over the next weeks to months; these items dictate when public quotes return. Confirm pricing with a broker until the OTC restores public dissemination.
SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today issued the following statement in response to recent shareholder inquiries regarding its current trading status on the OTC Expert Market and the display of a
The appearance of a
As previously disclosed in the Company’s Form 8-K filed on July 16, 2025, the Company received notice on July 14, 2025 from OTC Markets Group (“OTC”) that due to the Company’s failure to meet the requirement to stay current in its filings under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as required under the continued listing requirements of the OTC Pink Open Market, and the expiration of the grace period granted thereunder to post such filings, quotations in the Company’s shares of Common Stock were moved to the OTC Expert Market on or about July 17, 2025.
The OTC Expert Market is a quotation venue for securities of companies that are not current in their public disclosures. Due to regulatory restrictions, price quotes and trading data (such as bid/ask prices and volume) are not available to retail investors on most financial platforms. Only broker-dealers and institutional investors have access to real-time quote information, which is why some financial websites display a
It is important to note that the Company’s Common Stock is not delisted. The Company’s Common Stock is still tradable and listed, but because current financial information is not available, the OTC has restricted public price quotes. Instead, pricing information is now accessible only to brokers and market makers. This action ensures some level of market transparency even while the Company’s filings are being completed. Investors can still buy or sell the Company’s Common Stock but should consult with their brokers for the most up-to-date pricing and trading information.
Despite these current restrictions, the Company remains fully operational and is actively working to regain compliance with the reporting obligations under the Exchange Act. On October 8, 2025, the Company filed its Form 10-K for the year ended December 31, 2024. The Company is now focused on completing and filing its Form 10-Qs for the quarters ended March 31, June 30, and September 30, 2025, as part of its plan to become current as soon as possible with the Exchange Act’s reporting obligations.
The Company is committed to transparency, corporate compliance, and restoring full access to market information for all shareholders. Further updates will be provided as developments occur.
About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements
Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s anticipated timing and content of its filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public disclosures; the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. Additional risks include uncertainties related to the Company’s acquisition of a majority interest in NKMax, including risks regarding the future performance of NKMax’s business, the Company’s ability to successfully integrate NKMax’s operations, personnel, and technologies, potential challenges in realizing expected synergies and cost savings, and risks that the Company may not achieve the anticipated strategic, financial, or operational benefits of the acquisition on the expected timeline or at all. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the SEC’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:
Denise Chua, MBA, CLS, MLS (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com
External Contact:
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
FAQ
Why does NKGen (OTC:NKGN) show a $0.00 price on some financial websites?
Is NKGen common stock (NKGN) delisted after the OTC Expert Market move on July 17, 2025?
What filings has NKGen completed to regain compliance as of October 2025?
How can investors obtain current NKGN pricing and trading data while quotes are restricted?
What caused NKGen’s quotations to be moved to the OTC Expert Market in July 2025?
